BR9714065A - Sistema de fornecimento de micropartìculas de alvo biodegradáveis - Google Patents
Sistema de fornecimento de micropartìculas de alvo biodegradáveisInfo
- Publication number
- BR9714065A BR9714065A BR9714065-1A BR9714065A BR9714065A BR 9714065 A BR9714065 A BR 9714065A BR 9714065 A BR9714065 A BR 9714065A BR 9714065 A BR9714065 A BR 9714065A
- Authority
- BR
- Brazil
- Prior art keywords
- acid subunits
- alpha
- amino acid
- lactide
- serine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/68—Polyesters containing atoms other than carbon, hydrogen and oxygen
- C08G63/685—Polyesters containing atoms other than carbon, hydrogen and oxygen containing nitrogen
- C08G63/6852—Polyesters containing atoms other than carbon, hydrogen and oxygen containing nitrogen derived from hydroxy carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
- Y10S530/816—Attached to the carrier via a bridging agent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Biological Depolymerization Polymers (AREA)
- Polyesters Or Polycarbonates (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polyamides (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
<B>SISTEMA DE FORNECIMENTO DE MICROPARTìCULAS DE ALVO E BIODEGRADáVEIS<D> São descritos copolímeros projetados para uso como veículos em partículas contendo subunidades de aminoácido funcionalizáveis para acoplamento a ligantes de alvo. Os copolímeros são poliésteres compostos de subunidades de ácido <244>-hidroxi como subunidades de D, L-lactida e ácido pseudo- <244>-amino que podem ser derivadas de serina ou terpolímeros de subunidades de D, L-lactida e glicolida e de ácido pseudo - <244>-amino que podem ser derivadas de serina. São descritas preparações estáveis de vacina úteis como formulações de liberação retardada contendo antígeno ou antígenos e adjuvantes encapsulados em ou fisicamente misturados com micropartículas políméricas. Os veículos em partículas são úteis para fornecer agentes ao sistema imune de uma pessoa por vias de mucosa ou parenteral para produzir respostas imunes, incluindo respostas de anticorpo e de proteção.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/770,850 US6042820A (en) | 1996-12-20 | 1996-12-20 | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
PCT/CA1997/000980 WO1998028357A1 (en) | 1996-12-20 | 1997-12-19 | Biodegradable targetable microparticle delivery system |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9714065A true BR9714065A (pt) | 2000-10-24 |
Family
ID=25089888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9714065-1A BR9714065A (pt) | 1996-12-20 | 1997-12-19 | Sistema de fornecimento de micropartìculas de alvo biodegradáveis |
Country Status (13)
Country | Link |
---|---|
US (7) | US6042820A (pt) |
EP (1) | EP0946624B1 (pt) |
JP (3) | JP3242118B2 (pt) |
AT (1) | ATE236207T1 (pt) |
AU (1) | AU729305B2 (pt) |
BR (1) | BR9714065A (pt) |
CA (1) | CA2275033C (pt) |
DE (1) | DE69720516T2 (pt) |
DK (1) | DK0946624T3 (pt) |
ES (1) | ES2196385T3 (pt) |
NZ (1) | NZ336718A (pt) |
PT (1) | PT946624E (pt) |
WO (1) | WO1998028357A1 (pt) |
Families Citing this family (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9801288D0 (sv) * | 1998-04-14 | 1998-04-14 | Astra Ab | Vaccine delivery system and metod of production |
CA2335487A1 (en) | 1998-06-19 | 1999-12-23 | Merieux Oravax | Lt and ct in parenteral immunization methods against helicobacter infection |
US20070032853A1 (en) | 2002-03-27 | 2007-02-08 | Hossainy Syed F | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
US7807211B2 (en) * | 1999-09-03 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Thermal treatment of an implantable medical device |
DK1295611T3 (da) * | 2000-06-20 | 2010-10-04 | Dainippon Sumitomo Pharma Co | Oligonukleotid-transformerende forbindelser |
US20040033240A1 (en) * | 2000-07-05 | 2004-02-19 | Bruno Guy | Immunological combinations for prophylaxis and therapy of helicobacter pylori infection |
US20030092145A1 (en) * | 2000-08-24 | 2003-05-15 | Vic Jira | Viral vaccine composition, process, and methods of use |
US9974847B2 (en) * | 2000-08-24 | 2018-05-22 | Immunitor USA, Inc. | Treatment and prevention of tuberculosis |
US10398830B2 (en) * | 2000-11-17 | 2019-09-03 | Vactronix Scientific, Llc | Device for in vivo delivery of bioactive agents and method of manufacture thereof |
US8632845B2 (en) * | 2000-12-28 | 2014-01-21 | Abbott Cardiovascular Systems Inc. | Method of drying bioabsorbable coating over stents |
WO2002060486A2 (en) * | 2001-01-29 | 2002-08-08 | Fresco Bernard B | Controlled release microsphere system for administration of drug to the eye |
ES2324525T3 (es) * | 2001-06-20 | 2009-08-10 | Dainippon Sumitomo Pharma Co., Ltd. | Metodo para promover transferencia de acidos nucleicos. |
EP1438413A4 (en) * | 2001-10-03 | 2006-06-07 | Selective Genetics Inc | CROSSING OF NUCLEIC ACID MOLECULES IN A FLUID SPACE AND EXPRESSION IN REPAIR CELLS |
CA2457564C (en) * | 2001-10-05 | 2009-04-07 | Surmodics, Inc. | Particle immobilized coatings and uses thereof |
ATE410459T1 (de) * | 2002-01-14 | 2008-10-15 | Gen Hospital Corp | Bioabbaubare polyketale, verfahren zu ihrer herstellung sowie ihre verwendung |
US20040071780A1 (en) * | 2002-01-16 | 2004-04-15 | Lillard James W. | PACE-A microspheres for delivery of antigens |
US8088388B2 (en) * | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
US20050129776A1 (en) | 2002-05-03 | 2005-06-16 | Inserm | Microparticles supporting cells and active substances |
FR2839260B1 (fr) * | 2002-05-03 | 2005-02-25 | Inst Nat Sante Rech Med | Microparticules a base d'un materiau bicompatible et biodegradable, supportant des cellules et des substances biologiquement actives |
CA2486118A1 (en) * | 2002-06-07 | 2003-12-18 | Large Scale Biology Corporation | Flexible vaccine assembly and vaccine delivery platform |
US20040170606A1 (en) * | 2002-06-07 | 2004-09-02 | Palmer Kenneth E. | Production of peptides in plants as viral coat protein fusions |
AU2003269904A1 (en) * | 2002-07-10 | 2004-01-23 | The Ohio State University Research Foundation | Antigen-polymer compositions |
AU2003282372A1 (en) * | 2002-11-29 | 2004-06-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Process for preparation of biodegradable polymers and resins from proteins, and plastics obtained thereby |
WO2004092388A1 (ja) * | 2003-04-18 | 2004-10-28 | Japan As Represented By President Of National Cardiovascular Center | ベクター |
US20050118344A1 (en) | 2003-12-01 | 2005-06-02 | Pacetti Stephen D. | Temperature controlled crimping |
JP2005154514A (ja) * | 2003-11-21 | 2005-06-16 | Univ Waseda | 機能性生分解性材料およびその製造方法 |
EP1696034A4 (en) * | 2003-12-19 | 2006-12-27 | Dainippon Sumitomo Pharma Co | NUCLEIC ACID TRANSFER METHOD |
AU2005244128B2 (en) * | 2004-05-07 | 2009-06-25 | President And Fellows Of Harvard College | Pulmonary malarial vaccine |
EP2500031A3 (en) | 2005-02-24 | 2012-12-26 | Joslin Diabetes Center, Inc. | Compositions and Methods for Treating Vascular Permeability |
US20090062184A1 (en) * | 2005-03-24 | 2009-03-05 | Dainippon Sumitomo Pharma Co., Ltd. | Fine particulate preparation comprising complex of nucleic acid molecule and collagen |
US9603941B2 (en) * | 2006-01-24 | 2017-03-28 | Minghui Chai | Method of preparing dendritic drugs |
BRPI0711035A2 (pt) * | 2006-03-21 | 2011-08-23 | Dsm Ip Assests Bv | micropartìculas compreendendo um polìmero reticulado |
WO2008026894A1 (en) * | 2006-08-31 | 2008-03-06 | Sk Chemicals Co., Ltd. | Method for producing microspheres loaded with drugs and microspheres loaded with drugs produced thereby |
CA2684946C (en) | 2007-05-16 | 2015-03-31 | The Brigham And Women's Hospital, Inc. | Treatment of synucleinopathies |
US8551072B2 (en) * | 2007-12-12 | 2013-10-08 | Boston Scientific Scimed, Inc. | Methods, devices and compositions for controlled drug delivery to injured myocardium |
US20110208064A1 (en) | 2008-07-31 | 2011-08-25 | Ran Chongzhao | Curcumin Derivatives for Amyloid-Beta Plaque Imaging |
US9207242B2 (en) | 2008-10-09 | 2015-12-08 | The University Of Hong Kong | Cadherin-17 as diagnostic marker and therapeutic target for liver cancer |
EP3622968A1 (en) | 2008-10-31 | 2020-03-18 | The General Hospital Corporation | Compositions and methods for delivering a substance to a biological target |
JP5588993B2 (ja) * | 2008-11-14 | 2014-09-10 | イファ ユニバーシティ−インダストリー コラボレーション ファウンデーション | 高分子微粒球の製造方法及びその方法により製造された高分子微粒球 |
WO2010105096A2 (en) | 2009-03-11 | 2010-09-16 | University Of Massachusetts | Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212) |
EP2756845B1 (en) | 2009-04-03 | 2017-03-15 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA |
MX2011012597A (es) | 2009-05-27 | 2012-04-19 | Selecta Biosciences Inc | Nanoportadores que poseen componentes con diferentes tasas de liberacion. |
US20120208750A1 (en) | 2009-09-29 | 2012-08-16 | Joslin Diabetes Center, Inc. | Use of protein kinase c delta (pkcd) inhibitors to treat diabetes, obesity, and hepatic steatosis |
PT2525815E (pt) * | 2010-01-24 | 2015-03-05 | Novartis Ag | Micropartículas de polímero biodegradável irradiadas |
US20110224770A1 (en) * | 2010-03-15 | 2011-09-15 | Boston Scientific Scimed, Inc. | Drug Eluting Stents and Methods of Making the Same |
CN107080839A (zh) | 2010-05-26 | 2017-08-22 | 西莱克塔生物科技公司 | 多价的合成纳米载体疫苗 |
US9447027B2 (en) | 2010-10-22 | 2016-09-20 | The General Hospital Corporation | Treating long QT syndrome |
WO2012065182A2 (en) | 2010-11-12 | 2012-05-18 | University Of Massachusetts | Modulation of ubiquitination of synaptic proteins for the treatment of neurodegenerative and psychiatric disorders |
DE102011018499A1 (de) | 2011-04-23 | 2012-10-25 | Emc Microcollections Gmbh | Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut |
CN103702687A (zh) | 2011-07-29 | 2014-04-02 | 西莱克塔生物科技公司 | 产生体液和细胞毒性t淋巴细胞(ctl)免疫应答的合成纳米载体 |
WO2013075132A1 (en) | 2011-11-17 | 2013-05-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Therapeutic rna switches compositions and methods of use |
EP2836514A4 (en) | 2012-04-13 | 2015-12-30 | Childrens Medical Center | TIKI INHIBITORS |
EP4410374A2 (en) | 2012-05-08 | 2024-08-07 | Onyx Therapeutics, Inc. | Cylodextrin complexation methods for formulating peptide proteasome inhibitors |
WO2014025808A1 (en) | 2012-08-06 | 2014-02-13 | The General Hospital Corporation | Curcumin analogs |
WO2014065860A1 (en) | 2012-10-24 | 2014-05-01 | The General Hospital Corporation | Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions |
WO2014128257A1 (en) | 2013-02-22 | 2014-08-28 | Sanofi | Serpins: methods of therapeutic beta-cell regeneration and function |
EP2769732A1 (en) | 2013-02-22 | 2014-08-27 | Sanofi | Serpins: methods of therapeutic beta-cell regeneration and function |
EP2851086A1 (en) | 2013-09-20 | 2015-03-25 | Sanofi | Serpins: methods of therapeutic ß-cell regeneration and function |
WO2014159878A2 (en) | 2013-03-13 | 2014-10-02 | Regents Of The University Of California | Intranasal administration of guanidinylated aminoglycosides |
AR095426A1 (es) | 2013-03-14 | 2015-10-14 | Onyx Therapeutics Inc | Inhibidores tripeptídicos de la epoxicetona proteasa |
WO2014152127A1 (en) | 2013-03-14 | 2014-09-25 | Onyx Therapeutics, Inc. | Dipeptide and tripeptide epoxy ketone protease inhibitors |
US9737525B2 (en) | 2013-06-07 | 2017-08-22 | The General Hospital Corporation | Small molecule activators of NRF2 pathway |
US9757477B2 (en) | 2013-09-06 | 2017-09-12 | The General Hospital Corporation | Imaging brown adipose tissue with curcumin derivatives |
CN105142688B (zh) | 2014-02-04 | 2018-01-19 | 艾博特心血管系统公司 | 具有基于novolimus和丙交酯的涂层使得novolimus与涂层具有最小键合量的药物递送支架或支撑件 |
US10179775B2 (en) | 2014-08-11 | 2019-01-15 | The General Hospital Corporation | Cyclooctenes for bioorthogonol reactions |
JO3474B1 (ar) | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
AU2015346657B9 (en) | 2014-11-10 | 2020-01-16 | Evrys Bio, Llc | Anti-HCMV compositions and methods |
WO2016077240A2 (en) | 2014-11-10 | 2016-05-19 | Forge Life Science, Llc | Anti-hcmv compositions and methods |
US10420826B2 (en) | 2014-11-11 | 2019-09-24 | Massachusetts Eye & Ear Infirmary | Conjunctivitis vaccines |
JP7105065B2 (ja) | 2014-12-15 | 2022-07-22 | ダイセルナ ファーマシューティカルズ, インコーポレイテッド | リガンド修飾二本鎖核酸 |
SI3277814T1 (sl) | 2015-04-03 | 2020-12-31 | University Of Massachusetts | Oligonukleotidne spojine za ciljanja MRNA huntingtina |
SI3277815T1 (sl) | 2015-04-03 | 2022-01-31 | University Of Massachusetts | Ologonukleotidne spojine za zdravljenje preeklampsije in drugih angiogeneznih motenj |
AU2016256895B2 (en) | 2015-05-07 | 2022-05-26 | Takeda Pharmaceutical Company Limited | Glucocerebrosidase gene therapy for parkinson's disease |
US10633653B2 (en) | 2015-08-14 | 2020-04-28 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
EP4435105A2 (en) | 2015-09-29 | 2024-09-25 | Amgen Inc. | Asgr inhibitors for reduzing cholesterol levels |
AU2016355178B9 (en) | 2015-11-19 | 2019-05-30 | Massachusetts Institute Of Technology | Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity |
EP3380613B1 (en) | 2015-11-23 | 2022-10-26 | The Regents of the University of California | Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9 |
EP3408391A4 (en) | 2016-01-31 | 2019-08-28 | University of Massachusetts | BRANCHED OLIGONUCLEOTIDES |
WO2017147410A1 (en) | 2016-02-25 | 2017-08-31 | Amgen Inc. | Compounds that inhibit mcl-1 protein |
CA3033368A1 (en) | 2016-08-12 | 2018-02-15 | University Of Massachusetts | Conjugated oligonucleotides |
US10449230B2 (en) | 2016-10-06 | 2019-10-22 | The Regents Of The University Of California | Polymyxin derived cell penetrating scaffolds |
US10443055B2 (en) | 2016-12-22 | 2019-10-15 | Beth Israel Deaconess Medical Center | Compounds that target MYC microRNA responsive elements for the treatment of MYC-associated cancer |
JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Mcl−1タンパク質を阻害する化合物 |
CN110869498A (zh) | 2017-05-10 | 2020-03-06 | 加利福尼亚大学董事会 | 经由核递送crispr/cas9导向编辑细胞rna |
JP7406793B2 (ja) | 2017-06-23 | 2023-12-28 | ユニバーシティー オブ マサチューセッツ | 2テイル自己デリバリー型siRNAおよび関連方法 |
US20210128702A1 (en) | 2017-08-11 | 2021-05-06 | Dana-Farber Cancer Institute, Inc. | Use of a botulinum toxin agent for treating plasma cell disorders |
US11821003B2 (en) | 2017-08-14 | 2023-11-21 | Sanford Burnham Prebys Medical Discovery Institute | Cardiogenic mesoderm formation regulators |
US11364248B2 (en) | 2017-08-18 | 2022-06-21 | Amgen Inc. | Compounds that inhibit Mcl-1 protein |
MA50033A (fr) | 2017-08-29 | 2020-07-08 | Amgen Inc | Composés macrocycliques permettant d'inhiber la protéine mcl-1 |
WO2019046668A1 (en) | 2017-08-31 | 2019-03-07 | Kezar Life Sciences | AMIDE-SUBSTITUTED THIAZOLES AS INHIBITORS OF SECRETIC PROTEIN |
BR112020007879A2 (pt) | 2017-10-18 | 2020-10-13 | Evrys Bio, Llc | composições antivirais de amplo espectro e métodos |
WO2019089216A1 (en) | 2017-11-01 | 2019-05-09 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancers |
MA54985A (fr) | 2018-03-05 | 2021-12-29 | Amgen Inc | Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1 |
EP3790968A1 (en) | 2018-05-11 | 2021-03-17 | Alpha Anomeric SAS | Oligonucleotides conjugates comprising 7'-5'-alpha-anomeric-bicyclic sugar nucleosides |
SG11202101288TA (en) | 2018-08-10 | 2021-03-30 | Univ Massachusetts | Modified oligonucleotides targeting snps |
CA3110661A1 (en) | 2018-08-29 | 2020-03-05 | University Of Massachusetts | Inhibition of protein kinases to treat friedreich ataxia |
EP3893899A2 (en) | 2018-12-12 | 2021-10-20 | Kite Pharma, Inc. | Chimeric antigen receptors and car-t cells and methods of use |
AU2020228307A1 (en) | 2019-02-28 | 2021-09-23 | Kezar Life Sciences | Thiazole derivatives as protein secretion inhibitors |
EP3966328A4 (en) | 2019-05-06 | 2023-10-18 | University Of Massachusetts | ANTI-C9ORF72 OLIGONUCLEOTIDES AND RELATED METHODS |
JP2022547790A (ja) | 2019-08-09 | 2022-11-16 | ユニバーシティー オブ マサチューセッツ | Snpを標的とする化学修飾オリゴヌクレオチド |
CN110423338B (zh) * | 2019-08-12 | 2021-05-25 | 深圳市氩氪新材料技术研究服务有限公司 | 一种改性聚乳酸材料的制备方法 |
US12037585B2 (en) | 2019-12-23 | 2024-07-16 | University Of Massachusetts | Oligonucleotides for tissue specific gene expression modulation |
IL300736A (en) | 2020-08-31 | 2023-04-01 | Kezar Life Sciences | Protein secretion inhibitors |
BR112023026862A2 (pt) | 2021-06-23 | 2024-03-05 | Beth Israel Deaconess Medical Ct Inc | Compostos de oligonucleotídeos anti-flt1 otimizados para tratamento de pré-eclâmpsia e outros distúrbios angiogênicos |
AR128634A1 (es) | 2022-02-28 | 2024-05-29 | Kezar Life Sciences | Inhibidores de sec61 y uso de los mismos |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US30170A (en) * | 1860-09-25 | Improvement in plows | ||
US2676945A (en) | 1950-10-18 | 1954-04-27 | Du Pont | Condensation polymers of hydroxyacetic acid |
US3839297A (en) | 1971-11-22 | 1974-10-01 | Ethicon Inc | Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures |
USRE30170E (en) | 1975-04-04 | 1979-12-18 | Sutures, Inc. | Hydrolyzable polymers of amino acid and hydroxy acids |
DE3521994A1 (de) | 1985-06-20 | 1987-01-02 | Bayer Ag | N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
US5271945A (en) * | 1988-07-05 | 1993-12-21 | Takeda Chemical Industries, Ltd. | Sustained release microcapsule for water soluble drug |
US5248761A (en) | 1992-08-12 | 1993-09-28 | United States Surgical Corporation | Amino acid terminated polyesters having predetermined monomeric sequence |
US5399665A (en) * | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
US5593778A (en) * | 1993-09-09 | 1997-01-14 | Kanebo, Ltd. | Biodegradable copolyester, molded article produced therefrom and process for producing the molded article |
WO1995018781A1 (en) * | 1994-01-06 | 1995-07-13 | Metabolix, Inc. | Methods for synthesizing oligomers containing hydroxy acid units |
-
1996
- 1996-12-20 US US08/770,850 patent/US6042820A/en not_active Expired - Lifetime
-
1997
- 1997-12-19 ES ES97951024T patent/ES2196385T3/es not_active Expired - Lifetime
- 1997-12-19 EP EP97951024A patent/EP0946624B1/en not_active Expired - Lifetime
- 1997-12-19 US US09/331,118 patent/US6623764B1/en not_active Expired - Fee Related
- 1997-12-19 WO PCT/CA1997/000980 patent/WO1998028357A1/en active IP Right Grant
- 1997-12-19 AT AT97951024T patent/ATE236207T1/de active
- 1997-12-19 NZ NZ336718A patent/NZ336718A/xx not_active IP Right Cessation
- 1997-12-19 CA CA002275033A patent/CA2275033C/en not_active Expired - Fee Related
- 1997-12-19 DK DK97951024T patent/DK0946624T3/da active
- 1997-12-19 AU AU54721/98A patent/AU729305B2/en not_active Ceased
- 1997-12-19 PT PT97951024T patent/PT946624E/pt unknown
- 1997-12-19 JP JP52816998A patent/JP3242118B2/ja not_active Expired - Fee Related
- 1997-12-19 BR BR9714065-1A patent/BR9714065A/pt not_active IP Right Cessation
- 1997-12-19 DE DE69720516T patent/DE69720516T2/de not_active Expired - Lifetime
-
2000
- 2000-02-11 US US09/499,532 patent/US6471996B1/en not_active Expired - Fee Related
- 2000-02-11 US US09/502,674 patent/US6287604B1/en not_active Expired - Fee Related
- 2000-02-11 US US09/499,533 patent/US6312732B1/en not_active Expired - Fee Related
- 2000-02-11 US US09/501,373 patent/US6228423B1/en not_active Expired - Lifetime
-
2001
- 2001-07-23 JP JP2001255329A patent/JP3428972B2/ja not_active Expired - Fee Related
-
2003
- 2003-03-11 JP JP2003065795A patent/JP3990303B2/ja not_active Expired - Fee Related
- 2003-07-17 US US10/620,686 patent/US20050163745A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP3990303B2 (ja) | 2007-10-10 |
DK0946624T3 (da) | 2003-07-14 |
US6228423B1 (en) | 2001-05-08 |
CA2275033A1 (en) | 1998-07-02 |
US6287604B1 (en) | 2001-09-11 |
AU729305B2 (en) | 2001-02-01 |
EP0946624B1 (en) | 2003-04-02 |
ES2196385T3 (es) | 2003-12-16 |
EP0946624A1 (en) | 1999-10-06 |
JP2003261661A (ja) | 2003-09-19 |
US6312732B1 (en) | 2001-11-06 |
WO1998028357A1 (en) | 1998-07-02 |
JP3428972B2 (ja) | 2003-07-22 |
US6042820A (en) | 2000-03-28 |
JP2002138139A (ja) | 2002-05-14 |
JP3242118B2 (ja) | 2001-12-25 |
AU5472198A (en) | 1998-07-17 |
US6471996B1 (en) | 2002-10-29 |
NZ336718A (en) | 2001-01-26 |
PT946624E (pt) | 2003-08-29 |
US6623764B1 (en) | 2003-09-23 |
JP2000509428A (ja) | 2000-07-25 |
ATE236207T1 (de) | 2003-04-15 |
DE69720516T2 (de) | 2004-02-19 |
CA2275033C (en) | 2005-08-02 |
DE69720516D1 (de) | 2003-05-08 |
US20050163745A1 (en) | 2005-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9714065A (pt) | Sistema de fornecimento de micropartìculas de alvo biodegradáveis | |
Rharbaoui et al. | The Mycoplasma‐derived lipopeptide MALP‐2 is a potent mucosal adjuvant | |
Kipper et al. | Single dose vaccine based on biodegradable polyanhydride microspheres can modulate immune response mechanism | |
Mutwiri et al. | Combination adjuvants: the next generation of adjuvants? | |
Pham et al. | Exploiting cross-priming to generate protective CD8 T-cell immunity rapidly | |
AU7980794A (en) | Methods and compositions for microencapsulation of antigens for use as vaccines | |
Chen et al. | Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses | |
Arulanandam et al. | IL‐12 is a potent neonatal vaccine adjuvant | |
DE69532760D1 (de) | Mittel zur verabreichung von antigenen | |
ATE325200T1 (de) | Chimäre adenoviren | |
Bailey et al. | Self-encapsulating poly (lactic-co-glycolic acid)(PLGA) microspheres for intranasal vaccine delivery | |
CN103079589A (zh) | 用于诱导对抗原的免疫应答的靶向多表位剂型 | |
Bergmann-Leitner et al. | Complement 3d: from molecular adjuvant to target of immune escape mechanisms | |
Kovarik et al. | Optimization of vaccine responses in early life: the role of delivery systems and immunomodulators | |
EP4226938A3 (en) | Coronavirus vaccine | |
DK0686030T3 (da) | Med antigen ladede mikropartikler og farmaceutiske sammensætninger, som indeholder disse mikropartikler | |
WO2005007673A3 (en) | Immunogenic peptides | |
Demircan et al. | Biotin functionalized self‐assembled peptide nanofiber as an adjuvant for immunomodulatory response | |
Kovarik et al. | Adjuvant effects of CpG oligodeoxynucleotides on responses against T‐independent type 2 antigens | |
Johrden et al. | Comparison of polystyrene nanoparticles and UV-inactivated antigen-displaying adenovirus for vaccine delivery in mice | |
WO2004005325A3 (en) | Antigen-polymer compositions | |
WO1999063945A3 (en) | Vaccination strategy to prevent and treat cancers | |
WO1999053950A3 (en) | Live vaccines and methods of treatment therewith | |
DE60004334D1 (de) | Impfstoffzusammensetzung auf basis von partikeln | |
WO1998039027A3 (en) | Sialyl lewis antigens as targets for immunotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/12/1997, OBSERVADAS AS CONDICOES LEGAIS. |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 17A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2285 DE 21-10-2014 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |